Breast Cancer

Surgical Therapy

Adjuvant Therapy

1st Line MBC Therapy

2nd or 3rd Line MBC Therapy

Heavily Pre-Treated Therapy

HER2 POSITIVE

Pre-Op Therapy

S1501: Prospective Evaluation of Carvediolol in Prevention of Cardiac Toxicity in Patients with Metastatic HER2+ BC, Phase III

T-DM1 and Palbociclib in Metastatic HER2+ BC

T-DM1 and Tucatinib or Placebo in Metastatic HER2+ BC

Targeting Metastatic Breast Cancer and Breast Cancer Stem Cells with Lutathera

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment

CROSS-DISEASE TRIALS:

IRB# 6256
ISPY2
Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2

IRB # 19078
No Trial Currently Available

IRB #19830
No Trial Currently Available

IRB #19830
S1501: Prospective Evaluation of Carvediolol in Prevention of Cardiac Toxicity in Patients with Metastatic HER2+ BC, Phase III

IRB #20112
T-DM1 and Tucatinib or Placebo in Metastatic HER2+ BC

IRB #19489
Targeting Metastatic Breast Cancer and Breast Cancer Stem Cells with Lutathera

IRB#20679
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment

http://www.ohsu.edu/research/rda/so/knight.php

Key

Open for Enrollment

In Development

Enrollment on Hold

OHSU Knight Cancer Institute